Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease

Molecular Biology Reports

Volumn 38, Issue 8, 2011, Pages 5421-5428

  Vaisi Raygani, Asad ^a,b   Ghaneialvar, Hori ^b   Rahimi, Zohreh ^b,c   Tavilani, Haidar ^d   Pourmotabbed, Tayebeh ^e   Shakiba, Ebrahim ^b   Vaisi Raygani, Aliakbar ^b   Kiani, Amir ^b   Aminian, Mahdi ^f   Alibakhshi, Reza ^b   Bartels, Cynthia ^g  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF TENNESSEE   (United States)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Diabetes mellitus; Genetic polymorphism; Lipid profile; Paraoxonase; Vessel stenosis

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE CARRIER; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; IRAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARAOXANASE GENE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ALLELES; ARGININE; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DEMOGRAPHY; DIABETES COMPLICATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 84855224041     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0696-3     Document Type: Article

References (42)

1. Kharrazi H, Vaisi-Raygani A, Sabokroh AR, Pourmotabbed T (2006) Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem 39:613-616
2. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmo-tabbed T (2007) The presence of apolipoprotein e4 and e2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 40:1150-1156 (Pubitemid 47379326)
3. Rahimi Z, Vaisi-Raygani A, Pourmotaabed T (2010) Association between apolipoprotein e4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in Southern Iran. Mol Biol Rep 37(4):2083-2091
4. Vaisi Raygani A, Rahimi Z, Entezami H, Kharrazi H, Bahrhe-mand F, Tavilani H, Rezaei M, Kiani A, Nomanpour B, Tavilani H, Pourmotabbed T (2008) Butyrylcholinesterase K ariants increase the risk of coronary artery disease in the population of western Iran. Scand J Clin Lab Invest 68(2):123-129 (Pubitemid 351481736)
5. Vaisi Raygani A, Rahimi Z, Tavilani H, Pourmotabbed T (2010) Butyrylcholinesterase K variant and the APOE-e4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Bio Rep 37(4):2083-2091
6. Vaisi Raygani A, Tavilani H, Zahrai M, Rahimi Z, Sheikh N, Aminian M, Pourmotabbed T (2009) Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients. Clin Biochem 42:210-214
7. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A (2007) Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 7(32):1-5
8. Imazio M, Bobbio M, Bergerone S, Barlera S, Maggioni AP (1998) Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSI experience. J Ital Car-diol 28(5):505-512 (Pubitemid 28232426)
9. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahva-nainen E, Jauhi-ainen M (1996) The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98:883-885 (Pubitemid 26293303)
10. Gupta N, Gill K, Singh S (2009) Paraoxonases: Structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 130:361-368
11. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshina H et al (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569 (Pubitemid 28028569)
12. Pfohl M, Koch M, Enderle MD, Kühn R, Füllhase J, Karsch KR, Häring HU (1999) Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48:623-627 (Pubitemid 29106879)
13. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Hamda K, Farhat M, Miled A, Hammami M (2009) Association of homo-cysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 42:771-776
14. Davies HG (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336
15. La Du BN (1996) Structural and functional diversity of parao-xonases. Nat Med 2:1186-1187
16. Aviram M (1999) Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 5:66-78
17. Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur J Endocrin 144:639-644 (Pubitemid 32514819)
18. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
19. Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA (2010) The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 43:553-558
20. Aydin M, Gokkusu C, Ozkok E, Tulubas F, Unlucerci Y, Pam-ukcu B, Ozbek Z, Umman B (2009) Association of genetic variants in methylenetetrahydrofolate reductase and paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem 325:199-208
21. Odawara M, Tachi Y, Yamashitya K (1997) Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260 (Pubitemid 27287594)
22. Serrato M, Marian AJ (1995) A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008
23. Taskiran P, Cam SF, Sekuri C, Tuzun N, Alioglu E, Altintas N, Berdeli A (2009) The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Arch Turk Soc Cardiol 37(7):473-478
24. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Ha-mashige N, Hashimoto K (1996) Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57:69-73 (Pubitemid 26388830)
25. Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073 (Pubitemid 27260325)
26. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques Vidal P, Bard JM, Cambien F (1996) The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Athersclerosis 126:299-303 (Pubitemid 26336666)
27. World Health Organization (1999) WHO Study Group Report of a WHO consultation: part 1. Diagnosis and classification of diabetes mellitus. World Health Organization, Geneva
28. Johan SWM, Weitzner G, Rozen R (1991) A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 19:408
29. Crow JF (1999) Hardy, Weinberg and language impediments. Genetics 152(3):821-825 (Pubitemid 29330885)
30. Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE (2000) Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149:91-97 (Pubitemid 30125976)
31. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:686-695
32. Debbie T, Lawlor A, Day INM, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling M, Timpson N, Smith GD, Ebrahim S (2004) The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's heart and health cohort study and a meta-analysis. BMC Genetics 5(17):1-13
33. Aviram M, Fuhrman B (1998) LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol Cell Biochem 188:149-159 (Pubitemid 28493327)
34. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154
35. Tarchalski J, Guzik P, Wysocki H (2003) Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 246:25-30 (Pubitemid 36798718)
36. Steinberg D, Lewis A (1997) Conner Memorial Lecture. Oxida-tive modification of LDL and atherogenesis. Circulation 95:1062-1071 (Pubitemid 27091554)
37. Ajmal M, Ahmed W, Sadeque A, Ali SH, Bokhari SH, Ahmed N, Qamar R (2010) Identification of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia. Mol Biol Rep 37(8):3869-3875
38. AshokKumar M, Subhashini NG, SaiBabu R, Ramesh A, Cherian KM, Emmanuel C (2010) Genetic variants on apolipoprotein gene cluster influence triglycerides with a risk of coronary artery disease among Indians. Mol Biol Rep 37(1):521-527
39. Rahimi Z, Felehgari V, Rahimi M, Mozafari H, Yari K, Vaisi-Raygani A, Rezaei M, Malek-Khosravi S, Khazaie H (2011) The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angio-tensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep (in press)
40. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipo-protein oxidation and preserves its functions: a possible peroxi-dative role for PON1. J Clin Invest 101:1581-1590 (Pubitemid 28198486)
41. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, Aksoy N (2010) Nondiabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol 162(3):535-541
42. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum PON1 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60 (Pubitemid 28098579)